Earnings results for TherapeuticsMD (NASDAQ:TXMD)
TherapeuticsMD, Inc. is expected* to report earnings on 11/09/2020 before market open. The report will be for the fiscal Quarter ending Sep 2020. According to Zacks Investment Research, based on 4 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.14. The reported EPS for the same quarter last year was $-0.13.
TherapeuticsMD last released its quarterly earnings results on August 6th, 2020. The reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.02. The company had revenue of $10.70 million for the quarter, compared to analysts’ expectations of $11.93 million. TherapeuticsMD has generated ($0.68) earnings per share over the last year. TherapeuticsMD has confirmed that its next quarterly earnings report will be published on Monday, November 9th, 2020.
Analyst Opinion on TherapeuticsMD (NASDAQ:TXMD)
6 Wall Street analysts have issued ratings and price targets for TherapeuticsMD in the last 12 months. Their average twelve-month price target is $7.24, predicting that the stock has a possible upside of 493.44%. The high price target for TXMD is $15.00 and the low price target for TXMD is $1.20. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock, resulting in a consensus rating of “Buy.”
TherapeuticsMD has received a consensus rating of Buy. The company’s average rating score is 2.50, and is based on 4 buy ratings, 1 hold rating, and 1 sell rating. According to analysts’ consensus price target of $7.24, TherapeuticsMD has a forecasted upside of 493.4% from its current price of $1.22. TherapeuticsMD has only been the subject of 1 research reports in the past 90 days.
Dividend Strength: TherapeuticsMD (NASDAQ:TXMD)
TherapeuticsMD does not currently pay a dividend. TherapeuticsMD does not have a long track record of dividend growth.
Insiders buying/selling: TherapeuticsMD (NASDAQ:TXMD)
In the past three months, TherapeuticsMD insiders have not sold or bought any company stock. Only 13.76% of the stock of TherapeuticsMD is held by insiders. 55.72% of the stock of TherapeuticsMD is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Earnings and Valuation of TherapeuticsMD (NASDAQ:TXMD
Earnings for TherapeuticsMD are expected to grow in the coming year, from ($0.64) to ($0.29) per share. The P/E ratio of TherapeuticsMD is -1.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of TherapeuticsMD is -1.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. TherapeuticsMD has a P/B Ratio of 40.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
More latest stories: here